A questionnaire was sent to 400 general practitioners (GPs), concerning prostatespecific antigen (PSA) screening. Regarding the indications for PSA testing, 80% of GPs test men with urinary tract symptoms, 65% test men with a positive family history, 62% test on patient request, and 21% test men with unrelated symptoms. When PSA is measured, 91% of GPs inform their patient, and 71% discuss the significance of an abnormal result. The mean age range for PSA testing was from 50 years, without an upper age limit. The mode PSA threshold for referral was 6.6 ng/ml. De facto PSA screening appears to be widely practised.
Introduction
The use of prostate-specific antigen (PSA) as a mass population-screening test for prostate cancer is controversial. Guidelines from the national screening council state: 'The NHS will not be inviting men for PSA testing, and does not expect general practioners to raise the subject of PSA screening with asymptomatic male patients'.
1 However, men who ask for a PSA test are now eligible to have it performed after information is provided about the advantages and disadvantages of PSA testing, and any follow-up necessary will be provided by the NHS. This survey reports current PSA testing trends in general practice in Northern Ireland, and their workload implications.
Materials and methods

A cohort of 400 general practitioner (GP) Principals
within Northern Ireland was randomly selected by computer to receive a postal questionnaire. This consisted of six sections relating to PSA testing, with several questions within each section: (i) indications for PSA testing, (ii) investigations performed to test for prostate cancer, (iii) counselling before PSA testing, (iv) age groups for PSA testing, (v) response to abnormal PSA results, and (vi) PSA testing workload implications. A reminder letter was sent to the GPs after 4 weeks, if a reply had not been received from them. The full questionnaire is appended at the end of the article. Within the catchment area of the study, there is not a direct 'referral for biopsy' service available to GPs who refer patients with an elevated PSA. Patients are seen at the general urology clinic for counselling regarding the PSA result, and arrangements are made to perform a biopsy on a separate occasion. 2. In addition to this survey, the results of 353 PSA tests from a voluntary, self-referred PSA screening clinic were analysed. This clinic was run by a local cancer charity, organised and publicised by them, independent of the authors. Patients attending the clinic were counselled about the pros and cons of PSA testing and cancer screening, and then assessed by digital rectal examination and PSA testing. The results of this PSA test and examination findings were then passed on to the patient's GP, who would arrange follow-up as appropriate. The authors were permitted to analyse retrospectively the PSA results from this clinic, to establish the frequency of an abnormally elevated PSA in a self-referred cohort. The percentage of these patients with a PSA elevated sufficiently to a level to generate a urology outpatient referral was calculated, based on the mean PSA referral level of the GP cohort.
Results
The initial questionnaire response rate was 62%, rising to 71% after one reminder letter, which represents 282 responses from a cohort of 400 GPs.
When asked their opinion regarding which patients they arranged PSA testing for, the question was answered by 280 GPs. All men with lower urinary tract symptoms were tested by 224 (80%) of responding GPs, 182 (65%) tested men with a positive family history of prostatic carcinoma, 60 (21%) tested men who attended with unrelated symptoms, and 20 (7%) actively arranged PSA screening. PSA testing was performed for men who requested it by 175 (62%) of GPs. Several GPs who stated that they tested PSA on request commented that it was almost impossible to refuse such a request.
When testing for the presence of prostate cancer, there were 280 fully completed questions. The vast majority (244, 86%) of GPs used digital rectal examination combined with PSA to test for prostate cancer. The remainder used PSA only. Interestingly, 117 GPs (42%) also performed additional tests, of which the majority were blood tests. The most common of these was urea and electrolytes, which was tested by 31% of those using additional tests. The remaining blood tests used were: ESR 16%, full blood picture 15%, bone-profile 11%, liver function test 6%, C-reactive protein 2% and glucose 1%. Urinary tract infection was tested for by only 16% of GPs, using either dipstick analysis or MSSU.
Regarding counselling prior to PSA testing, 255 (91%) GPs advised patients when PSA was being tested within a group of blood tests and 199 (71%) discussed the implications if an abnormally elevated result was to be found. Prostate cancer treatment was discussed in general terms at the time of initial PSA testing by 49(18%) of GPs.
The age ranges where PSA testing was used as a screening test were variable, but both the mean and mode lower age limit for PSA testing was 50 y. There was no upper age limit to testing. In the screening context, the percentage of GPs who selected a beginning to screening and discontinuation age ranges are documented in Figure 1 .
The response to an abnormal PSA result was completed by 257 GPs. When a PSA result returned as abnormal, 212 (88%) of GPs counselled the patient before referral to urology outpatients, 142 (55%) repeated the test, and 64 (25%) referred directly without counselling. Many GPs commented that they would be content to repeat a test showing only a modest elevation, but would refer any significant elevation in PSA directly. The PSA value that would constitute a modest rise was not specified. The mode PSA threshold range for referral is between 6.6 and 10 ng/ml. The percentage of GPs who would refer a patient for biopsy above a PSA level of 2.6, 4.0, 6.6, and 10 ng/ml was 2, 34, 73 and 100%, respectively. Using these figures to establish a linear trend line for referral, the median threshold for referral is 5.4 ng/ml ( Figure 2 ). Only 11% of practices have a policy regarding abnormal PSA results.
The PSA results of 353 men who attended the voluntary PSA screening clinic were reviewed. The mean age of the men was 62 y (range 48-74 y). Of this group, 16 men (4.5%) had a PSA level greater than the mode referral threshold of 6.6 ng/ml. If the trend line threshold is applied, the figure rises to 19 men (5.4%). If a lower threshold of 4 ng/ml was applied, this figure increased to 35 men (9.3%).
The change in workload that PSA screening would produce if widely publicised was thought to be moderate by 150 of 269 GPs (54%) who responded to this question. Of the remainder, 60 (22%) thought it would generate a large amount of extra work, 56 (21%) thought it would produce a small amount of additional work, and only 3 (1%) of responding GPs believed it would not increase workload at all.
Discussion
At present there is no clear evidence to support or refute PSA screening. The controversy surrounding it is likely to continue for several years until the results of large-scale multicentre randomised trials regarding screening obtain the statistical power to show definitive results. The European Randomised Screening for Prostate Cancer trial (ERSPC) estimate that they will be able to show definitive results between 2005 and 2008. 2 The results suggest that opportunistic PSA testing is widespread, especially among those with lower urinary Testing starts Testing ends Figure 1 'In which age groups would you use PSA as a screening test for prostate cancer?' Results of GP cohort indicating the frequency with which each age range was the lowest age group for PSA testing, and which age range was the highest for PSA testing. This perhaps reflects the fact that patients who are symptomatic, or who wish to request screening, are likely to present themselves to the surgery, and do not need to be formally called for testing, as would be the case in true screening programmes. This is reflected in the very low rate of GPs who actively arrange appointments for PSA testing. Interestingly, although selective male PSA screening is practised, only one GP out of five will screen patients who attend with unrelated complaints, which suggests that current screening selection is limited to exclusively those with outflow symptoms, a positive family history, or who specifically ask for PSA to be tested. Usual practice of the vast majority of GPs when testing for prostate cancer is to use both PSA and DRE. Previous published work indicates that the positive predictive value of an abnormal DRE is 16-18%, compared to 17-28% for an abnormal PSA alone. When combined, the positive predictive value rises to 51-56%. If an age-specific reference PSA level is used, then the positive predictive value rises to 64% if both are abnormal. 3, 4 There is a high incidence of other associated tests in the present survey, which reflects the fact that 80% of PSA tests are done in the context of men who have presented with lower urinary tract symptoms or, much less frequently, are having a PSA checked within a group of other blood tests. Interestingly, given that a urinary tract infection can induce a PSA rise, only one in six GPs perform either an MSSU or urinary dipstick test. Perhaps, the inclusion of dipstick urinalysis as part of routine PSA testing would help to reduce the frequency with which abnormal results are obtained, particularly as a urinary tract infection may produce changes in bladder habit similar to outflow obstruction.
The majority of GPs advise a patient when PSA is tested and the significance of an abnormal result, indicating that the current national screening council guidelines are being adhered to. It also suggests that consent, albeit verbal, is being obtained for PSA screening prior to testing. Few GPs explain about prostate cancer treatment, perhaps because prostate cancer treatment guidelines are not widely publicised, or because the absence of a direct referral for biopsy service within the catchment area ensures that counselling will be performed at urology outpatients. The national screening council website (http:/ /www.nelc.org. uk/docs/psa) has several versions of patient information leaflets that describe the pros and cons of PSA screening. Leaflet use prior to the consultation would perhaps help patients to decide whether they wish to pursue screening.
Two-thirds of GPs think PSA will produce a moderate to large workload increase if widely publicised. Screening has substantial cost and workload implications. The UK has a population of 58 789 184 people, according to the results of the national census 2001. 5 The number aged between 45 and 75 y who are male is 9 216 314, that is, 16% of the population. In the above study, the cost of a PSA test was d5; so excluding the costs of staffing and premises, the cost of performing a PSA on every man within this age group would be approximately d46 million, potentially repeated on an annual basis, and excluding hospital treatment or investigation costs. The workload implications are also substantial. Aside from the 9 million screening consultations annually, if 9.3% of PSA tests are abnormal and are subsequently biopsied, 850 000 biopsies will be required. For these reasons, further research as to the efficacy of PSA screening is being undertaken prior to initiating national screening. Only one study has shown a decrease in the prostate cancer death rate from screening. This was the Quebec 1988 screening trial of 46 193 men, which showed a significant fall in the prostate cancer-specific death rate from 49/100 000 to 15/100 000. 6 However, this study has attracted criticism for its statistical methods, central to which was the fact that only 23% of the trial population were willing to participate and that there was compromise of the randomisation process between groups. Recently, a new analysis of the Quebec population has shown that there was no correlation between the decrease in mortality and PSA screening. This suggests that the original paper's results should be regarded with caution. 7 The use of PSA as a screening test is controversial. A survey of GPs in New Zealand showed that over two-thirds screen at least some of the male population over 50 y, and 40% believe all men over 50 y should be screened. 8 Just as in our study, where the vast majority of GPs will perform PSA test on request, after discussing its implications, this New Zealand study observed that 62% of GPs would PSA test on request. Patients also initiated the majority of PSA testing in a Quebec study (66%), which also noted that 73% of PSA tests were conducted as part of a routine medical examination. 9 About 20% of Canadian men have had PSA screening at least once.
In the above study, the apparent norm in general practice is to test PSA from the age of 50 y, without an age ceiling. This is analogous to a previous study analysing PSA testing in general practice, which found that the frequency of PSA testing does not change significantly between age groups between 60 and 80 y old. 10 Although several screening studies regard age 75 as their upper age limit 3, 11 , most suggest an upper age limit of 70 y. 12 The lower age limit is less well defined, but is usually 45 to 50 y. 3, 11, 12 Men with a family history of prostate cancer have a higher risk of prostate cancer, and this is reflected in the high percentage of GPs in our study who PSA test men who have a relative with prostate cancer. 13 The frequency with which screening is performed was not formally assessed in our study. Screening is often carried out on an annual basis, but recent analysis has suggested that screening every 2 y may be sufficient. 14 In our study, despite it not being a strict screening project, did define that the mode threshold for referral to a urologist was between 6.6 and 10 ng/ml, and the trend median was 5.4 ng/ml, which is higher than most other screening studies. Using 6.6 ng/ml as a threshold for referral, 4.5% of screened PSA tests will merit referral to a urologist. Our study also showed that 9.3% of screened PSA tests were above 4.0 ng/ml, which is similar to previously reported studies, where 8-20% may be greater than 4.0 ng/ml, leading to a 1.2-3% cancer detection rate.
3,12,15-18 An alternative to using a rigid PSA value to define an abnormality is to use age-referenced PSA testing in general practice B Little et al values, as PSA tends to rise with age. 3, 12, 18 If age-specific PSA is used, then fewer PSA tests are abnormal (8.8%), and more biopsies are positive (27%). 12 Additional information can be obtained by the free to total PSA ratio. If the total PSA is less than 10 ng/ml, then 94% of cancers will exhibit a free to total ratio of 18% or less, and 42% of negative biopsies would be eliminated. 3 A prospective study by the same group recommended a slightly higher cutoff value of 22%, which detected 98% of cancers, and reduced the negative biopsy rate by 30%. 3 However, for screening purposes, free to total PSA ratio is not sufficient in itself to act as a screening test without the use of total PSA. 19 Even with proactive screening programmes, some men refuse to attend. In the ERSPC trial in Rotterdam, it was found that these men were significantly more likely to be single, older, generally less healthy but with fewer urological symptoms, and had a lower education standard. 20 The most common reasons cited for nonattendance were: absence of urological complaints (57%) and anticipated discomfort of screening (18%). Kirby et al 17 evaluated anxiety following screening, and found that 69% of screened men were not unduly concerned by it. Of his group that had undergone biopsy, 89% had felt little or no discomfort associated with the procedure. 17 
Conclusion
PSA screening remains unproven, but is widely practised on selected patients, provided they present to a general practitioner. The potential workload and cost implications are very substantial. Screening is best performed using PSA and digital rectal examination. If screening were to be performed on asymptomatic men, the usual age range would be from 50 to 70 y, possibly 45 to 75 y. PSA screening may be carried out every 2 y. The use of age-specific PSA levels increases the cancer detection rate without unduly increasing the biopsy rate. Free to total PSA ratios below 22% are more likely to be because of malignancy, and may reduce the total biopsy rate. The results of multicentre trials are anticipated in 2005-2008. 
